IRD — Opus Genetics Share News
0.000.00%
Last trade - 00:00- $317.81m
- $265.20m
- $14.20m
U.S. STOCKS ON THE MOVE-Coinbase, Best Buy, Abercrombie & Fitch
Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage
Brief: Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Brief: Opus Genetics Inc Enters Agreements For Private Placement Of Shares
Opus Genetics Inc reports results for the quarter ended June 30 - Earnings Summary
Opus Genetics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Opus Genetics Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint For Phentolamine Ophthalmic Solution
Brief: Opus Genetics Says Nirav Jhaveri Departs As CFO - SEC Filing
Brief: Opus Genetics Inc - Secures Up To $2 Million Funding From RD Fund
Opus Genetics Inc reports results for the quarter ended March 31 - Earnings Summary
Opus Genetics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Mina Sooch Issues Open Letter To Opus Genetics' Stockholders
Brief: Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To Board
Brief: Opus Genetics Inc - Terminates Purchase Agreement With Lincoln Park - SEC Filing
Brief: Opus Genetics founder Mina Sooch files preliminary proxy materials for co board election
Brief: Opus Genetics In Jan, Got Paragraph IV Certification Notice From Winston & Strawn, Counsel To Sandoz Incorporated
Opus Genetics Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Opus Genetics Announces Updates On Opgx-Lca5 Clinical Program
Brief: Opus Genetics Files For Offering Of Up To $40 Mln Common Stock - SEC Filing